Actions for Pharmacoeconomic review report [electronic resource] : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy. Ixekizumab (Taltz) (Eli Lilly Canada Inc.).

View MARC record | catkey: 44554300